Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants.

Mathy FX, Dohin E, Bonfitto F, Pelgrims B.

Eur Heart J. 2019 May 14;40(19):1571. doi: 10.1093/eurheartj/ehy780. No abstract available.

2.

Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Giladi N, Nicholas AP, Asgharnejad M, Dohin E, Woltering F, Bauer L, Poewe W.

J Parkinsons Dis. 2016 Oct 19;6(4):741-749.

3.

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.

Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L.

BMC Neurol. 2016 Jun 7;16:90. doi: 10.1186/s12883-016-0610-7.

4.

Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.

Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E, Goldammer N, Schollmayer E, Schröder H, Winkelman JW.

Am J Kidney Dis. 2016 Sep;68(3):434-43. doi: 10.1053/j.ajkd.2015.12.027. Epub 2016 Feb 3.

PMID:
26851201
5.

A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L.

J Clin Pharmacol. 2016 Jul;56(7):852-61. doi: 10.1002/jcph.678. Epub 2015 Dec 31.

PMID:
26626320
6.

Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.

Garcia-Borreguero D, Allen R, Hudson J, Dohin E, Grieger F, Moran K, Schollmayer E, Smit R, Winkelman J.

Curr Med Res Opin. 2016;32(1):77-85. doi: 10.1185/03007995.2015.1103216. Epub 2015 Nov 16.

PMID:
26569149
7.

Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.

Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, Schmid M, Singh P, Tolosa E, Chaudhuri KR.

Eur J Neurol. 2015 Oct;22(10):1400-7. doi: 10.1111/ene.12757. Epub 2015 Jun 22.

PMID:
26095948
8.

Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.

Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW.

Expert Opin Pharmacother. 2015;16(10):1423-33. doi: 10.1517/14656566.2015.1049597. Epub 2015 May 22.

PMID:
25997442
9.

Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.

Dohin E, Högl B, Ferini-Strambi L, Schollmayer E, Fichtner A, Bauer L, García-Borreguero D.

Expert Opin Pharmacother. 2013 Jan;14(1):15-25. doi: 10.1517/14656566.2013.758251. Epub 2012 Dec 21.

PMID:
23256574
10.

A case of efflorescence of cutaneous warts as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient.

Kerob D, Dupuy A, Vignon-Pennamen MD, Bournerias I, Dohin E, Lebbe C.

Clin Infect Dis. 2007 Aug 1;45(3):405-6. No abstract available.

PMID:
17599331
11.

[Compliance, efficacy and quality of life].

Bergmann JF, Dohin E, Juillet Y; Giens XVII.

Therapie. 2002 Jul-Aug;57(4):366-78. French.

PMID:
12422557
12.

MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.

Katlama C, Pellegrin JL, Lacoste D, Aquilina C, Raffi F, Pialoux G, Vittecoq D, Raguin G, Lantz O, Mouroux M, Calvez V, Trylesinski A, Montestruc F, Dohin E, Goehrs JM, Delfraissy JF.

HIV Med. 2001 Jan;2(1):20-6.

13.

Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.

Michelet C, Ruffault A, Sébille V, Arvieux C, Jaccard P, Raffi F, Bazin C, Chapplain JM, Chauvin JP, Dohin E, Cartier F, Bellissant E.

Antimicrob Agents Chemother. 2001 Dec;45(12):3393-402.

14.

Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model.

Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L.

Am J Obstet Gynecol. 2001 Jul;185(1):178-81.

PMID:
11483925
15.

Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.

Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, Do B, Trylesinski A, Diquet B, Dohin E, Delfraissy JF, Katlama C, Calvez V.

J Clin Microbiol. 2000 Jul;38(7):2726-30.

16.

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.

Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.

Clin Pharmacol Ther. 1999 Jun;65(6):661-71.

PMID:
10391672
17.

Nelfinavir-induced urticaria and successful desensitization.

Demoly P, Messaad D, Trylesinski A, Faucherre V, Fabre J, Reynes J, Delmas C, Dohin E, Godard P, Bousquet J.

J Allergy Clin Immunol. 1998 Nov;102(5):875-6. No abstract available.

PMID:
9819308
18.

Measuring quality of life from the point of view of HIV-positive subjects: the HIV-QL31.

Leplège A, Rude N, Ecosse E, Ceinos R, Dohin E, Pouchot J.

Qual Life Res. 1997 Aug;6(6):585-94.

PMID:
9330557
19.

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P.

Ann Intern Med. 1996 Nov 1;125(9):705-12.

PMID:
8929003
20.

Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison.

Blanshard C, Benhamou Y, Dohin E, Lernestedt JO, Gazzard BG, Katlama C.

J Infect Dis. 1995 Sep;172(3):622-8.

PMID:
7658052
21.

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.

Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M.

Lancet. 1995 Feb 11;345(8946):396-7. No abstract available.

PMID:
7845151
22.

AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients.

Benhamou Y, Caumes E, Gerosa Y, Cadranel JF, Dohin E, Katlama C, Amouyal P, Canard JM, Azar N, Hoang C, et al.

Dig Dis Sci. 1993 Jun;38(6):1113-8.

PMID:
8389687
23.

Foscarnet-induced vulvar erosion.

Caumes E, Gatineau M, Bricaire F, Dohin E, Katlama C, Gentilini M.

J Am Acad Dermatol. 1993 May;28(5 Pt 1):799. No abstract available.

PMID:
8496435
24.

Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Taburet AM, Katlama C, Blanshard C, Zorza G, Gazzard D, Dohin E, Gazzard BG, Frostegard C, Singlas E.

Antimicrob Agents Chemother. 1992 Sep;36(9):1821-4.

25.

Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.

Katlama C, Dohin E, Caumes E, Cochereau-Massin I, Brancon C, Robinet M, Rogeaux O, Dahan R, Gentilini M.

J Acquir Immune Defic Syndr. 1992;5 Suppl 1:S18-24.

PMID:
1318363
26.

[Long-term effects of splenectomy for immune thrombopenic purpura related to human immunodeficiency virus. A retrospective study from 2 groups, with and without splenectomy].

Gabarre J, Azar N, Ben Othman T, Gharakhanian S, De Sahb R, Dohin E, Sansonetti P, Langlois P, Chigot JP, Echard M, et al.

Presse Med. 1991 Dec 21-28;20(44):2239-45. French.

PMID:
1838164
27.

[Pentamidine aerosol in the preventive treatment of pneumocystosis in AIDS patients. Comparison of two salts and two nebulizers].

Dautzenberg B, Antoun F, Broussier PM, Dohin E, Farinotti R.

Presse Med. 1991 Jun 22;20(24):1117-20. French.

PMID:
1830145
28.

Foscarnet and crystals in glomerular capillary lumens.

Beaufils H, Deray G, Katlama C, Dohin E, Henin D, Sazdovitch V, Jouanneau C.

Lancet. 1990 Sep 22;336(8717):755. No abstract available.

PMID:
1975929
29.

Prevention of foscarnet nephrotoxicity.

Deray G, Katlama C, Dohin E.

Ann Intern Med. 1990 Aug 15;113(4):332. No abstract available.

PMID:
2165372
30.

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, Rozenheim M, Baumelou A, Dohin E, Gentilini M, et al.

Am J Nephrol. 1989;9(4):316-21.

PMID:
2554731

Supplemental Content

Support Center